NP49425 Generic and Biosimilar Transition Medicines
Estimated value
£131.2m
Awarded value
—
Suppliers
0
Lots
9
Published
05 Aug 2025
This is a preliminary market engagement notice
Map the supplier landscape and document your shortlist before opening the tender. The market simulation produces a defensible audit record you can attach to your procurement file.
Total lots
9
Awarded
0
Estimated total
£234.9m
Awarded total
—
Cancer Medicines (Group 2)
Start
01 Feb 2026
End
31 Jan 2027
Estimated
£15.2m
CPV
Cytokine Modulators
Start
01 Feb 2026
End
28 Feb 2027
Estimated
£100.0m
CPV
Gastrointestinal, Endocrine, Nutrition, Blood, and Multiple Sclerosis Medicines
Start
31 Mar 2026
End
28 Feb 2027
Estimated
£15.6m
CPV
Denosumab (osteoporosis)
Start
01 Feb 2026
End
31 Jul 2027
Estimated
£26.2m
CPV
Apremilast
Start
01 Feb 2026
End
31 Jul 2027
Estimated
£27.4m
CPV
Cardiovascular and Respiratory Medicines
Start
01 Feb 2026
End
31 Oct 2027
Estimated
£1.5m
CPV
Nintedanib
Start
01 Feb 2026
End
30 May 2028
Estimated
£457k
CPV
Cancer Medicines (Group 1)
Start
31 Mar 2026
End
30 May 2028
Estimated
£27.3m
CPV
Neurology Medicines
Start
01 Feb 2026
End
31 Jan 2027
Estimated
£21.3m
CPV